Amicus Therapeutics Announces Second Quarter 2022 Financial Results
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: GlobeNewswire
1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7% On-Track to Deliver Full-Year Double-Digit Revenue Growth of 15-20% at Constant Exchange Rates Advancing U.S. and EU Regulatory Reviews and Launch Preparations for AT-GAA in Pompe Disease 3 Newly Issued U.S. Composition of Matter Patents for Galafold Add to Growing U.S. Patent Portfolio Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended June 30, 2022. Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “Through the first half of the year and into the third quarter, we have gained great momentum towards achieving our key strategic priorities
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable? [Yahoo! Finance]Yahoo! Finance
- Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportGlobeNewswire
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $19.00. They now have an "overweight" rating on the stock.MarketBeat
FOLD
Earnings
- 2/28/24 - Beat
FOLD
Sec Filings
- 4/16/24 - Form 4
- 4/15/24 - Form 144
- 4/3/24 - Form 4
- FOLD's page on the SEC website